Recent News

• 11.11.2025 - Webcast from AHA to Discuss Olezarsen CORE and CORE2 Data
• 10.07.2025 - Innovation Day 2025
• 10.07.2025 - Innovation Day 2025
• 09.22.2025 - Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
• 09.19.2025 - TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
• 09.12.2025 - Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
• 09.09.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.09.2025 - Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
• 09.08.2025 - Ionis to host investors and analysts for Innovation Day 2025
• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference

Recent Filings

• 09.22.2025 - EX-99.1 EX-99.1
• 09.22.2025 - 8-K Current report
• 09.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities